- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Dicarboxylic acid.
Displaying page 1 of 1.
EudraCT Number: 2013-004198-28 | Sponsor Protocol Number: BAY1000394/14615 | Start Date*: 2014-06-18 |
Sponsor Name:Bayer AG | ||
Full Title: A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who a... | ||
Medical condition: extensive-stage disease small cell lung cancer (ED SCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) HU (Completed) IT (Completed) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000113-70 | Sponsor Protocol Number: NA | Start Date*: 2016-04-30 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: Clinical efficacy and mechanistic evaluation of Eplerenone for Central serous chorio-retinopathy – the VICI randomised trial. | |||||||||||||
Medical condition: Central serous chorio-retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004946-41 | Sponsor Protocol Number: SP-PP18 | Start Date*: 2019-09-12 |
Sponsor Name:Dr. Virgilio P. Carnielli, | ||
Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial | ||
Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004155-39 | Sponsor Protocol Number: BAY1000394/14858 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer | |||||||||||||
Medical condition: Subjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000868-42 | Sponsor Protocol Number: B3461045 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003351-12 | Sponsor Protocol Number: A6141079 | Start Date*: 2005-10-27 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure | |||||||||||||
Medical condition: Chronic systolic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IE (Completed) SK (Completed) SE (Completed) GB (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
